OLT1177 (dapansutrile) has subsequently been reported to be an inhibitor of the NLRP3 ATPase [365] and has demonstrated safety and efficacy in reducing IL-1-mediated inflammation in conditions such as gout, heart failure, and autoimmune encephalomyelitis [366–368]. Here, IL1B is linked to gout.